LadRx Corporation (LADX)
OTCMKTS · Delayed Price · Currency is USD
0.0500
0.00 (0.00%)
Apr 1, 2026, 9:30 AM EST
LadRx Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
25.25K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aridis Pharmaceuticals | 22.36M |
| GeneLink | 1.58M |
| Trevena | 546.00K |
| America Great Health | 382.86K |
| U.S. Stem Cell | 82.05K |
| Health Sciences Group | 69.31K |
| NanoLogix | 1.27K |
LadRx News
- 1 year ago - LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th - GlobeNewsWire
- 1 year ago - LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates - Business Wire
- 2 years ago - LadRx Issues 2024 Update to Shareholders - Business Wire